oxymatrine
Small moleculeexperimental
Oxymatrine is one of many quinolizidine alkaloid compounds extracted from the root of Sophora flavescens, a Chinese herb. It is very similar in structure to matrine, which has one less oxygen atom. Oxymatrine has a variety of effects in vitro and in animal models, including protection against apoptosis, tumor and fibrotic tissue development, and inflammation. Furthermore, oxymatrine has been shown to decrease cardiac ischemia, myocardial injury, arrhythmias, and improve heart failure by increasing cardiac function. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Jul 24, 2014 (NCT02202473)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOxymatrine ↗
Also known as
- oxymatrine
- oxymatrine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02202473 | Phase 4 | Jul 24, 2014 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Southeast University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 1 | 0 | 1 | 2014 |
| Southeast University | Academic/Hospital | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1